Gland PharmaNSE:GLAND +0.40%84 3-Year ROIIC % is 5.32 as of Mar. 2026, which is 171% above its 10-year median of 1.96. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,136.46 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 944 Drug Manufacturers companies, Gland Pharma ranks better than 52.01% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Gland Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 5.32%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Gland Pharma's 3-Year ROIIC % or its related term are showing as below:
NSE:GLAND's 3-Year ROIIC % is ranked better than 52.01% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs NSE:GLAND: 5.32
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Gland Pharma 3-Year ROIIC % Related Terms
Gland Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Gland Pharma (NSE:GLAND) has a 3-Year ROIIC % of 5.32 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gland Pharma and its competitors. This is 171% above median its historical median of 1.96. According to the industry distribution chart, Gland Pharma ranks #453 out of 944 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Gland Pharma's 3-Year ROIIC % too high?
Gland Pharma's current 3-Year ROIIC % of 5.32 is 171% above median its 10-year median of 1.96. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Gland Pharma's value of 5.32 is 46.4% above this industry median. Based on the distribution chart, Gland Pharma ranks #453 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #453 out of 944 companies for 3-Year ROIIC %. This puts Gland Pharma in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. Gland Pharma's value of 5.32 is 46.4% above this benchmark. While the company's 10-year median is 1.96 vs. the industry median of 3.64, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current 3-Year ROIIC % of 5.32 is 46.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current 3-Year ROIIC % is 5.32, which is 171% above median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,136.46, compared to a current price of ₹2,479.40 — trading 16.1% above its estimated fair value. The current 3-Year ROIIC % is 5.32, which is 171% above median its 10-year median of 1.96 and 46.4% above the Drug Manufacturers industry median of 3.64. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current 3-Year ROIIC % is 5.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,479.40 is trading 16.1% above its estimated GF Value™ of ₹2,136.46.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
3-Year ROIIC %: 5.32 (171% above median its 10-year median of 1.96)
GF Value™: ₹2,136.46 vs. price of ₹2,479.40 (16.1% above fair value)
Industry Position: 46.4% above the Drug Manufacturers median (#453 of 944)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
